June 9, 2020 / 9:52 PM / a month ago

BRIEF-Denali Therapeutics Inc - Provides Broad Update On Its Ripk1 Program Partnered With Sanofi

June 9 (Reuters) - Denali Therapeutics Inc:

* DENALI THERAPEUTICS INC - PROVIDES BROAD UPDATE ON ITS RIPK1 PROGRAM PARTNERED WITH SANOFI

* DENALI THERAPEUTICS INC - DENALI AND SANOFI PAUSE DNL747 CLINICAL ACTIVITIES

* DENALI THERAPEUTICS INC - CO, SANOFI INTEND TO ACCELERATE DNL788 FOR DEVELOPMENT IN NEUROLOGICAL INDICATIONS

* DENALI THERAPEUTICS INC - SAFETY ENDPOINTS WERE MET IN PHASE 1B PATIENT STUDIES WITH DNL747 IN ALS AND ALZHEIMER’S DISEASE

* DENALI THERAPEUTICS - TO PAUSE DNL747 CLINICAL ACTIVITIES BASED ON TOTALITY OF DNL747 DATA, SUPERIOR PROFILE OF BACKUP COMPOUND DNL788 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below